Amazon and Caremark could haunt CVS/Aetna

In the coming months, antitrust enforcers at the Department of Justice will decide whether and how CVS Health’s $69 billion acquisition of Aetna might harm consumers – a question shaded by a history of consolidation across the healthcare industry and the potential for new, powerful entrants to disrupt the industry.

Unlock unlimited access to all Global Competition Review content